These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 9341097)

  • 21. Interpretation of male rat renal tubule tumors.
    Rodgers IS; Baetcke KP
    Environ Health Perspect; 1993 Dec; 101 Suppl 6(Suppl 6):45-52. PubMed ID: 7517352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. alpha 2-Urinary globulin-associated nephropathy as a mechanism of renal tubule cell carcinogenesis in male rats.
    Swenberg JA; Lehman-McKeeman LD
    IARC Sci Publ; 1999; (147):95-118. PubMed ID: 10457913
    [No Abstract]   [Full Text] [Related]  

  • 23. Hazard evaluation of chemicals that cause accumulation of alpha 2u-globulin, hyaline droplet nephropathy, and tubule neoplasia in the kidneys of male rats.
    Hard GC; Rodgers IS; Baetcke KP; Richards WL; McGaughy RE; Valcovic LR
    Environ Health Perspect; 1993 Mar; 99():313-49. PubMed ID: 7686485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible mechanisms of induction of renal tubule cell neoplasms in rats associated with alpha 2u-globulin: role of protein accumulation versus ligand delivery to the kidney.
    Melnick RL; Kohn MC
    IARC Sci Publ; 1999; (147):119-37. PubMed ID: 10457914
    [No Abstract]   [Full Text] [Related]  

  • 25. Rodent carcinogenicity bioassay: past, present, and future.
    Boorman GA; Maronpot RR; Eustis SL
    Toxicol Pathol; 1994; 22(2):105-11. PubMed ID: 7973358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Criteria, rules and procedures adopted by IARC in evaluating risks from different carcinogenic agents for humans].
    IARC
    Vopr Onkol; 2007; 53(6):621-41. PubMed ID: 18416130
    [No Abstract]   [Full Text] [Related]  

  • 27. Carcinogenicity of lipid-lowering drugs.
    Newman TB; Hulley SB
    JAMA; 1996 Jan; 275(1):55-60. PubMed ID: 8531288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
    Radi Z; Bartholomew P; Elwell M; Vogel WM
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):456-63. PubMed ID: 24141031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human relevance of animal carcinogenicity studies.
    Cohen SM
    Regul Toxicol Pharmacol; 1995 Feb; 21(1):75-80; discussion 81-6. PubMed ID: 7784639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.
    Osimitz TG; Droege W; Boobis AR; Lake BG
    Food Chem Toxicol; 2013 Oct; 60():550-62. PubMed ID: 23954551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemically induced cell proliferation in carcinogenesis in the male rat kidney.
    Short BG; Swenberg JA
    Prog Clin Biol Res; 1991; 369():357-67. PubMed ID: 1946532
    [No Abstract]   [Full Text] [Related]  

  • 33. What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database.
    Gold LS; Slone TH; Ames BN
    Drug Metab Rev; 1998 May; 30(2):359-404. PubMed ID: 9606609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relevance of rodent tumors in assessing carcinogenicity in human beings.
    Kuschner M
    Regul Toxicol Pharmacol; 1995 Apr; 21(2):250-1. PubMed ID: 7644714
    [No Abstract]   [Full Text] [Related]  

  • 35. Nitrobenzene carcinogenicity in animals and human hazard evaluation.
    Holder JW
    Toxicol Ind Health; 1999 Aug; 15(5):445-57. PubMed ID: 10487355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of transgenic mice in carcinogenicity hazard assessment.
    Jacobson-Kram D; Sistare FD; Jacobs AC
    Toxicol Pathol; 2004; 32 Suppl 1():49-52. PubMed ID: 15209403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk assessment of ochratoxin A residues in food.
    Kuiper-Goodman T
    IARC Sci Publ; 1991; (115):307-20. PubMed ID: 1820347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of mechanisms of acrylamide carcinogenicity.
    Besaratinia A; Pfeifer GP
    Carcinogenesis; 2007 Mar; 28(3):519-28. PubMed ID: 17234719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ochratoxin A carcinogenicity involves a complex network of epigenetic mechanisms.
    Marin-Kuan M; Cavin C; Delatour T; Schilter B
    Toxicon; 2008 Aug; 52(2):195-202. PubMed ID: 18649906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relevance of quantitation of benzo(a)pyrene metabolites in animal excretes to evaluate individual human cancer risk.
    Likhachev AJ; Beniashvili DSh; Bykov VJ; Dikun PP; Tyndyk ML; Savochkina IV; Yermilov VB; Zabezhinski MA
    Prog Clin Biol Res; 1992; 374():435-52. PubMed ID: 1620717
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.